Cargando…

PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study()()

PURPOSE: Performance of anatomical metrics of Response Evaluation Criteria in Solid Tumors (RECIST1.1) versus Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST1.0) for neoadjuvant chemoradiation (nCR) of pancreatic adenocarcinoma was evaluated based on the pathological treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalah, Entesar, Tai, An, Oshima, Kiyoko, Hall, William A, Erickson, Beth, Li, X. Allen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070701/ https://www.ncbi.nlm.nih.gov/pubmed/30015263 http://dx.doi.org/10.1016/j.tranon.2018.06.011

Ejemplares similares

Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer
por: Dalah, Entesar, et al.
Publicado: (2018)

Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study
por: Chen, Xiaojian, et al.
Publicado: (2017)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer
por: Wittmann, David, et al.
Publicado: (2020)

Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
por: Galindo, José, et al.
Publicado: (2013)

Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9
por: Nasief, Haidy, et al.
Publicado: (2020)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
por: Hartley, Christopher, et al.
Publicado: (2020)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
por: Matani, Hirsch, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series
por: Gorbudhun, Rachna, et al.
Publicado: (2022)

Chemoradiation After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma is it of Proven Benefit?
por: Garden, O. J.
Publicado: (1999)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
por: Crocenzi, Todd, et al.
Publicado: (2016)

Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas
por: Pompa, Tiffany A., et al.
Publicado: (2017)

Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles
por: Lee, Sung Hwan, et al.
Publicado: (2015)

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer
por: Dayde, Delphine, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
por: Hadzitheodorou, Christina, et al.
Publicado: (2017)

Exploratory Analysis of Serial (18)F-fluciclovine PET-CT and Multiparametric MRI during Chemoradiation for Glioblastoma
por: Fatania, Kavi, et al.
Publicado: (2022)

A Pilot Study of Diffusion-Weighted MRI in Patients Undergoing Neoadjuvant Chemoradiation for Pancreatic Cancer
por: Cuneo, Kyle C., et al.
Publicado: (2014)

Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer
por: Ashida, Reiko, et al.
Publicado: (2020)

Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials
por: Fu, Tao, et al.
Publicado: (2015)

Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: a retrospective analysis
por: Koch, Oliver O., et al.
Publicado: (2019)

The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma
por: Buka, David, et al.
Publicado: (2017)

Residual lymph node disease and mortality following neoadjuvant chemoradiation and curative esophagectomy for distal esophageal adenocarcinoma
por: Kandilis, Apostolos, et al.
Publicado: (2020)

Neoadjuvant Chemoradiation Herapy for Soft Tissue Sarcomas of the Extremities
por: Aguiar, Samuel, et al.
Publicado: (2009)

Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation
por: Dricken, Julie, et al.
Publicado: (2020)

Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment
por: Suwanthanma, Weerapat, et al.
Publicado: (2021)

Regression Analysis between the Different Breast Dose Quantities Reported in Digital Mammography and Patient Age, Breast Thickness, and Acquisition Parameters
por: Dhou, Salam, et al.
Publicado: (2022)

The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement
por: Lee, Jin Ho, et al.
Publicado: (2015)

Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation
por: Nelson, Bailey, et al.
Publicado: (2022)

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)
por: van Heijl, M, et al.
Publicado: (2008)

Assessing visceral and subcutaneous adiposity using segmented T2-MRI and multi-frequency segmental bioelectrical impedance: A sex-based comparative study
por: Dalah, Entesar Z., et al.
Publicado: (2021)

Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
por: Hsu, Charles C., et al.
Publicado: (2010)

Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma
por: Habermehl, Daniel, et al.
Publicado: (2015)

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma
por: Jain, Anish J., et al.
Publicado: (2023)

Induction Fluorouracil-Based Chemotherapy and PET-Adapted Consolidation Chemoradiation with Esophagectomy for High-Risk Gastroesophageal Adenocarcinoma
por: Sinnamon, Andrew J., et al.
Publicado: (2023)

Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015)

Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients
por: Warnecke-Eberz, Ute, et al.
Publicado: (2020)

Variations of MRI-assessed peristaltic motions during radiation therapy
por: Mostafaei, Farshad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uab0llsfd5couu1cbb4tqpks5g